Business News: Crown Labs Reduces Revance Therapeutics’ Buyout Price
Revance has agreed to a lower-priced buyout from Crown Laboratories. Under the new terms, which have been unanimously approved by Revance’s Board of Directors, Crown will commence a tender offer to acquire all outstanding shares of Revance’s common stock for $3.10 per share in cash instead of the $6.66 per share agreed upon previously. The […]